全文获取类型
收费全文 | 26373篇 |
免费 | 2574篇 |
国内免费 | 468篇 |
专业分类
耳鼻咽喉 | 113篇 |
儿科学 | 473篇 |
妇产科学 | 513篇 |
基础医学 | 1081篇 |
口腔科学 | 1342篇 |
临床医学 | 6219篇 |
内科学 | 4199篇 |
皮肤病学 | 726篇 |
神经病学 | 1646篇 |
特种医学 | 415篇 |
外国民族医学 | 2篇 |
外科学 | 2845篇 |
综合类 | 1985篇 |
现状与发展 | 1篇 |
预防医学 | 2356篇 |
眼科学 | 229篇 |
药学 | 2273篇 |
7篇 | |
中国医学 | 1062篇 |
肿瘤学 | 1928篇 |
出版年
2024年 | 89篇 |
2023年 | 1041篇 |
2022年 | 2209篇 |
2021年 | 2972篇 |
2020年 | 1809篇 |
2019年 | 1672篇 |
2018年 | 1298篇 |
2017年 | 1413篇 |
2016年 | 1040篇 |
2015年 | 809篇 |
2014年 | 1562篇 |
2013年 | 1840篇 |
2012年 | 1100篇 |
2011年 | 1128篇 |
2010年 | 929篇 |
2009年 | 942篇 |
2008年 | 1000篇 |
2007年 | 962篇 |
2006年 | 902篇 |
2005年 | 734篇 |
2004年 | 579篇 |
2003年 | 466篇 |
2002年 | 384篇 |
2001年 | 298篇 |
2000年 | 229篇 |
1999年 | 222篇 |
1998年 | 210篇 |
1997年 | 154篇 |
1996年 | 148篇 |
1995年 | 112篇 |
1994年 | 106篇 |
1993年 | 77篇 |
1992年 | 101篇 |
1991年 | 100篇 |
1990年 | 124篇 |
1989年 | 105篇 |
1988年 | 126篇 |
1987年 | 101篇 |
1986年 | 62篇 |
1985年 | 47篇 |
1984年 | 41篇 |
1983年 | 27篇 |
1982年 | 16篇 |
1981年 | 28篇 |
1980年 | 25篇 |
1979年 | 17篇 |
1978年 | 11篇 |
1977年 | 10篇 |
1976年 | 8篇 |
1975年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
6.
《Vaccine》2022,40(27):3721-3726
We initiated a randomized, placebo-controlled, phase 1/2 trial to evaluate the safety and immunogenicity of the S-268019-b recombinant protein vaccine, scheduled as 2 intramuscular injections given 21 days apart, in 60 randomized healthy Japanese adults. We evaluated 2 regimens of the S-910823 antigen (5 μg [n = 24] and 10 μg [n = 24]) with an oil-in-water emulsion formulation and compared against placebo (n = 12). Reactogenicity was mild in most participants. No serious adverse events were noted. For both regimens, vaccination resulted in robust IgG and neutralizing antibody production at days 36 and 50 and predominant T-helper 1-mediated immune reaction, as evident through antigen-specific polyfunctional CD4+ T-cell responses with IFN-γ, IL-2, and IL-4 production on spike protein peptides stimulation. Based on the interim analysis, the S-268019-b vaccine is safe, produces neutralizing antibodies titer comparable with that in convalescent serum from COVID-19-recovered patients. However, further evaluation of the vaccine in a large clinical trial is warranted. 相似文献
7.
8.
9.
《Vaccine》2021,39(42):6333-6339
Px563L is a next-generation anthrax vaccine candidate consisting of a protein subunit, mutant recombinant protective antigen SNKE167-ΔFF-315-E308D (mrPA), and liposome-embedded monophosphoryl lipid A (MPLA) adjuvant. Px563L has the potential to deliver an improved safety and immunogenicity profile relative to the currently licensed vaccine, which is produced from filtered B. anthracis culture supernatants.We conducted a Phase 1, double–blind, placebo–controlled, dose–escalation study in 54 healthy subjects to evaluate Px563L at 3 dose levels of mrPA (10, 50, and 80 mcg). For each dose level, 18 subjects were randomized in an 8:8:2 ratio to Px563L (mrPA with adjuvant), RPA563 (mrPA only) or placebo (saline). Each subject received an intramuscular (IM) injection on Day 0 and Day 28. Primary safety and immunogenicity analysis was conducted after all subjects completed the Day 70 visit, a duration deemed clinically relevant for post-exposure prophylaxis. Long-term safety was assessed through Day 393.Vaccinations with Px563L at all dose levels were well-tolerated. There were no serious adverse events or adverse events (AE) leading to early withdrawal. In all treatment groups, most AEs were due to injection site reactions, and all AEs at the 10 and 50 mcg dose levels were mild. For the primary immunogenicity endpoint (protective toxin neutralizing antibody 50% neutralization factor [TNA NF50]), titers started to increase significantly after the second administration of Px563L, from Day 35 through Day 70, with the geometric mean and lower bound of the 95% confidence interval exceeding 0.56, a threshold correlating with significant survival in animal models of anthrax exposure.In conclusion, Px563L, administered as two IM doses 28 days apart, was well-tolerated and elicited a protective antibody response starting at seven days after the second vaccination. These findings support the continued development of Px563L in a two-dose regimen for anthrax post-exposure prophylaxis. ClinicalTrials.gov identifier NCT02655549. 相似文献
10.
Zongzhang Huang Qigu Yao Jianping Zhu Ying He Yanghao Chen Feng Wu Teng Hua 《Diagnostic and interventional imaging》2021,102(5):279-285
PurposeThe purpose of this study was to make a systematic review and meta-analysis to determine the stent diameter (8 mm vs. 10 mm) that conveys better safety and clinical efficacy for transjugular intrahepatic portosystemic shunt (TIPS).Materials and methodsFour databases were used to identify clinical trials published from inception until March 2020. Data were extracted to estimate and compare one-year and three-year overall survivals, hepatic encephalopathy, variceal rebleeding, and shunt dysfunction rates between patients with 8 mm covered stents and those with 10 mm covered stents.ResultsFive eligible studies were selected, which included 489 patients (316 men, 173 women). The 8 mm covered stent group had higher efficacy regarding one-year or three-year overall survival (odds ratio [OR], 2.88; P = 0.003) and (OR, 1.81; P = 0.04) and lower hepatic encephalopathy (OR, 0.69; P = 0.04) compared with 10 mm covered stent group. There were no significant differences in variceal rebleeding rate (OR 0.80; P = 0.67). However, shunt dysfunction was lower in 10 mm covered stent group (OR, 2.26; P = 0.003).ConclusionsOur results suggest that the use of 8 mm covered stents should be preferred to that of 10 mm covered stents for TIPS placement when portal pressure is frequently monitored. 相似文献